Project Description

Ramandeep K. Brar, MD, FACC, FHRS

Dr. Ramandeep K. Brar joined Los Alamitos Cardiovascular in 2006. Dr. Brar is board certified in Cardiac Electrophysiology, Nuclear Cardiology, Cardiovascular Disease and Internal Medicine. In January 2016, Dr. Brar became Director of Cardiac Electrophysiology at Los Alamitos Medical Center (LAMC), and she was concurrently appointed as LAMC’s Chair of Medicine. Dr. Brar has also chaired LAMC’s Physician Leadership Council, and she is vice chair of LAMC’s Credentialing Committee. Dr. Brar is Director of the Pacemaker Clinic at Los Alamitos Cardiovascular and a partner in the practice, as well.

As a specialist in cardiovascular care, I provide care in conjunction with your primary care physician. In order to optimize well-being and comfort, it is imperative for the patient to play an active role in understanding their treatment and in the management of their health…

On Los Alamitos Cardiovascular

Our team represents all the facets of cardiology required to provide outstanding patient care, with the latest knowledge and techniques. I am honored to be a part of this excellent group of well-rounded cardiologists dedicated to improving the health and well-being of patients.

Dr. Ramandeep K. Brar’s Curriculum Vitae

Click here to download as a PDF

Specialties

Cardiovascular Diseases, Cardiac Electrophysiology and Nuclear Cardiology

Board Certifications

  • Certified in Clinical Cardiac Electrophysiology
    American Board of Internal Medicine
    November 2010
  • Certified in Nuclear Cardiology
    Board of Nuclear Cardiology
    December 2007
  • Certified in Cardiovascular Disease
    American Board of Internal Medicine
    November 2006 (Recertification 2017)
  • Certified in Internal Medicine
    American Board of Internal Medicine
    August 2001 (Recertification 2011)
  • Expert Reviewer
    The Medical Board of California
    August 2014-Present

Current Hospital Appointments

  • Los Alamitos Medical Center
    3751 Katella Avenue
    Los Alamitos, California 90720
  • MemorialCare Health System
    Long Beach Memorial Medical Center
    2801 Atlantic Avenue
    Long Beach, California 90801
  • UCLA Ronald Reagan Medical Center
    757 Westwood Plaza
    Los Angeles, CA 90095

Committees

Los Alamitos Medical Center

  • Director, Cardiac Electrophysiology
    Effective January 2016
  • Chair, Medicine
    Effective January 2016
  • Chair, Physician Leadership Council
    July 2014-August 2017
  • Vice Chair, Medicine
    January 2014-December 2015
  • Vice Chair, Credentials
    Effective January 2013

Professional Societies

  • American College of Cardiology (FACC)
    Fellow
  • Heart Rhythm Society (FHRS)
    Fellow

Publications

  • Anthony P, Chandraratna N, Skeikh Y, Brar R, Kim D. “Feasibility of Continuous Cardiac Imaging Using a Novel Ultrasound Transducer.” Circulation: Journal of American Heart Association: Abstracts from the 71st Scientific Sessions.
  • Anthony P, Chandraratna N, Skeikh Y,  Brar R, Khan Z, Chen Q. “Continuous Recording of Pulmonary Artery Diastolic pressure and cardiac Output using a Novel Ultrasound Transducer.” Circulation: Journal of the American Heart Association: Abstracts from the 71st Scientific Sessions.
  • Chandraratna P, Brar R, Agioian E, Vijaysekara S. “Using of a Novel Chest Wall Attachable Ultrasound Transducer for Continuous Bedside Monitoring of Left Ventricular Regional Wall Motion Abnormalities.”
  • Anthony P,  Chandraratna N, Brar R, Vijaysekaran S, Chen Q.“Feasibility of Continuous Transthoracic imaging Using a Novel Ultrasound Transducer.“
  • Anthony N, Chandraratna N, Brar R, Vijaysekaran S, Sheikh Y. “Continuous Recording of Pulmonary Artery Diastolic Pressure and Cardiac Output Using a Novel Ultrasound Transducer.” Echocardiography.
  • Brar R, Attai S, Brar PK,  Butler M, Chandraratna P. “Echocardiographic Evaluation of Left Ventricular Systolic Function.” Cardiac Ultrasound Today 2003; Vol 9: Number 5.

Education

  • Cardiac Electrophysiology Fellowship
    University of California, Los Angeles
    July 2005 –  August 2006
  • Cardiovascular Diseases Fellowship
    University of California, Irvine
    July 2002 – July 2005
  • Chief Resident, Internal Medicine
    3rd Year
    Cornell University Medical Center/ Wyckoff Heights Medical Center
    July 2000 – June 2001
  • Residency Training
    Internal Medicine
    Cornell University Medical Center/ Wyckoff Heights Medical Center
    July 1998 –  June 2001
  • Rotatory Internship
    Dayanand Medical College and Hospital Ludhiana, Punjab, India
    January 1996 – June 1997
  • MBBS /MD
    Dayanand Medical College and Hospital Ludhiana
    Punjab, India
    August 1991 –  December 1995

Educational Honors and Awards

  • Intern of the Year Department of Internal Medicine
    June 1999
    Cornell University Medical Center/ Wyckoff Heights Medical Center
  • Intern of the Month Department of Internal Medicine
    August 1998
    Cornell University Medical Center/ Wyckoff Heights Medical Center

Research Experience

  • AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome.
    Sub-Investigator | 2019
    Sponsor: CSL Behring LLC
    NCT03473223: https://clinicaltrials.gov/ct2/show/NCT03473223
  • COVET : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
    Principal Investigator | 2018 – Present
    Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
    NCT03196349: https://clinicaltrials.gov/ct2/show/NCT03196349
  • NODE 301: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
    NCT03464019: https://clinicaltrials.gov/ct2/show/NCT03464019
  • NODE 302: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
    Sub-Investigator | 2019
    Sponsor: Milestone Pharmaceuticals Inc.
    NCT03635996: https://clinicaltrials.gov/ct2/show/NCT03635996
  • PARADISE MI: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
    Sub-Investigator | 2018 – Present
    Sponsor: Novartis
    NCT02924727: https://clinicaltrials.gov/ct2/show/NCT02924727
  • PEA-VALVE: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
    Principal Investigator | 2018 – Present
    Sponsor: Eko Devices
  • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
    Principal Investigator | 2017 – Present
    Sponsor: Amgen
    NCT02929329 | https://clinicaltrials.gov/ct2/show/NCT02929329
  • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Sub-Investigator | 2017 – 2019
    Sponsor: Novartis
    NCT02887183 | https://clinicaltrials.gov/ct2/show/NCT02887183
  • Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo – Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
    Principal Investigator | 2016 – Present
    Sponsor: CVRx, Inc.
    NCT02627196 | https://clinicaltrials.gov/show/NCT02627196
  • MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
    Principal Investigator | 2016 – 2017
    Sponsor: Gilead/ICON
  • THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS – Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
    Sub-Investigator | 2015 – Present
    Sponsor: AstraZeneca
    NCT01991795 | https://clinicaltrials.gov/show/NCT01991795 
  • Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
    Sub-Investigator | 2015 – 2016
    Sponsor: Amgen, Evidera
  • DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
    Principal Investigator | 2013 – 2018
    Sponsor: AstraZeneca
    NCT01730534 | https://clinicaltrials.gov/ct2/show/NCT01730534
  • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
    Sub-Investigator | 2013 – 2017
    Sponsor: Sanofi
    NCT01663402 | https://clinicaltrials.gov/ct2/show/NCT01663402
  • SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
    Sub-Investigator | 2013 – 2017
    Sponsor: Yale University School of Medicine/NIH
    NCT01755052 | https://clinicaltrials.gov/ct2/show/NCT01755052
  • RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
    Principal Investigator | 2013 – 2014
    Sponsor:  Janssen Scientific Affairs/Johnson & Johnson
  • Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
    Principal Investigator | 2013
    Sponsor: Tasly Pharmaceuticals
    NCT0169580 | https://clinicaltrials.gov/ct2/show/NCT01659580
  • Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
    Principal Investigator | 2013 – 2018
    Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
    NCT01594333 | https://clinicaltrials.gov/ct2/show/NCT01594333
  • User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2PT/INR Monitoring System (ADAPT) BSTE-0159.
    Principal Investigator | 2012
    Sponsor: Alere San Diego
  • Mission® PT Coagulation Monitoring System Clinical Study.
    Sub-Investigator | 2012
    Sponsor: ACON Laboratories, INC.
  • The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
    Principal Investigator | 2012 – 2015
    Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
    NCT00786474 | https://clinicaltrials.gov/ct2/show/NCT00786474
  • GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
    Principal Investigator | 2012 – Present
    Sponsor: Boehringer Ingelheim
    NCT01468701 | https://clinicaltrials.gov/ct2/show/NCT01468701
  • California State Elective Percutaneous Coronary Intervention Pilot Program
    Principal Investigator | 2010 – 2014
  • BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
    Sub-Investigator | 2010 – 2012
    Sponsor: St. Jude Medical Center
    NCT01062126 | https://clinicaltrials.gov/ct2/show/NCT01062126
  • The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
    Principal Investigator | 2010 – 2014
    Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
    NCT01174550 | https://clinicaltrials.gov/ct2/show/NCT01174550
  • ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Principal Investigator | 2010 – 2017
    Sponsor: Janssen Scientific Affairs, LLC
    Collaborator: Duke Clinical Research
    NCT01165710 | https://clinicaltrials.gov/ct2/show/NCT01165710
    NCT01701817 | https://clinicaltrials.gov/ct2/show/NCT01701817
  • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00837798 | https://clinicaltrials.gov/ct2/show/NCT00837798
  • FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00418314 | http://clinicaltrials.gov/ct2/show/NCT00418314
  • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation – Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE – AF TIMI – 48).
    Principal Investigator | 2009 – 2015
    Sponsor: Daiichi Sankyo Pharma Development
    NCT00781391 | http://clinicaltrials.gov/ct2/show/NCT00781391